Prof. Stroes discusses the efficacy of PCSK9 inhibitors and which patients benefit most from LDL-c lowering (combination) therapies.

This posthoc analysis of the ENGAGE AF-TIMI 48 trial demonstrated no difference in efficacy and safety of edoxaban vs. warfarin in AF patients with extreme body weight compared to middle body weight.

Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.

In a subanalysis of the DAPA-HF study, dapagliflozin improved CV outcomes in HFrEF patients when compared to placebo, irrespective of baseline SBP.

Compared to those who reported no alcohol intake, T2DM patients with moderate (>7 drinks/week) and heavy (>14 drinks/week) alcohol consumption had increased risk of elevated BP, hypertension grade I and hypertension grade 2.

What is the role of triglyceride-rich lipoproteins in residual risk in patients with ASCVD?

This subanalysis of the ODYSSEY OUTCOME trial evaluated whether the effects of alirocumab, compared to placebo, on MACE and all-cause death are influenced by renal function in patients with recent ACS.

Three experts discuss the findings of the EVAPORATE study in detail and how to interpret these. The EVAPORATE trial examined the effect of icosapent ethyl on plaque formation and was a mechanistic study for the REDUCE-IT trial.

Prof. Lam discusses important effects of comorbidities in HF patients and how these comorbidities may affect the use of treatments for HF.

Attainment of 2016 guideline-recommended risk-based LDL-c goal was 54% and 33% of 2019 risk-based LDL-c goal in patients on lipid-lowering therapy in primary and secondary settings.

The FDA has granted Fast Track designation for empagliflozin to reduce hospitalization for HF and mortality in patients with and without T2DM following an acute MI.

Prof. Mach discusses the concepts for lipid lowering treatment as defined in the 2019 ESC/EAS dyslipidemia guidelines.